Pioneer and leader of interactive respiratory products accelerates commercialization with clinivation’s Reimbursement Strategy Solution.
Framingham, MA, April 16, 2007 – clinivation, Inc. announced today that InterCure Ltd. has selected clinivation’s Reimbursement Strategy Solution.
“InterCure has developed next-generation technology for the treatment of cardiovascular and pulmonary diseases,” said Joseph Kozikowski, M.D., clinivation’s Chief Executive Officer. “We are pleased that InterCure has selected clinivation to help develop a reimbursement strategy for their lead respiratory product,” he continued.
Clinivation’s reimbursement strategy solutions integrate all aspects of a successful clinical strategy including regulatory, reimbursement, and marketing objectives.
About InterCure Ltd.
InterCure, a medical device company, has become a leader in the growing Personal Therapeutic Device category. Its broadly patented “device-guided breathing” technology platform enables a systematic reduction in sympathetic outflow of the autonomous nervous system. InterCure is successfully selling the world’s 1st hypertension treatment device, RESPeRATE. With multiple published clinical trials, regulatory approvals in most key markets (FDA over-the-counter (“OTC”) clearance, CE mark, Chinese SDA, and others) and a renowned scientific advisory board, RESPeRATE is rapidly becoming a part of the standard of care for the treatment of hypertension.
For more information, please visit www.intercure.com.
